These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17484513

  • 1. Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins.
    Mozzanega B, Babbo GL, Salmaso L, De Toni R, Schiavo A, Mioni R, de Kreutzenberg SV.
    Gynecol Endocrinol; 2007 Jan; 23(1):50-7. PubMed ID: 17484513
    [Abstract] [Full Text] [Related]

  • 2. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens.
    Biglia N, Ambroggio S, Ponzone R, Sgro L, Ujcic E, Dato FA, Sismondi P.
    Maturitas; 2003 Aug 20; 45(4):283-91. PubMed ID: 12927315
    [Abstract] [Full Text] [Related]

  • 3. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels.
    Cano A, Castelo-Branco C, Tarín JJ.
    Fertil Steril; 1999 Feb 20; 71(2):261-7. PubMed ID: 9988395
    [Abstract] [Full Text] [Related]

  • 4. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy.
    Wang HS, Wang TH, Soong YK.
    Hum Reprod; 2000 Jan 20; 15(1):50-4. PubMed ID: 10611187
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.
    Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE.
    Clin Endocrinol (Oxf); 1996 Dec 20; 45(6):727-32. PubMed ID: 9039339
    [Abstract] [Full Text] [Related]

  • 6. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ, Ho KK, Lazarus L.
    J Clin Endocrinol Metab; 1991 Feb 20; 72(2):374-81. PubMed ID: 1991807
    [Abstract] [Full Text] [Related]

  • 7. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS, Jørgensen JO.
    Eur J Endocrinol; 2005 May 20; 152(5):719-26. PubMed ID: 15879357
    [Abstract] [Full Text] [Related]

  • 8. Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women.
    Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska-Gluszak U, Srzednicki M, Brzezinska A, Zgliczynski W, Sadowski Z.
    J Endocrinol Invest; 1992 May 20; 15(7):533-8. PubMed ID: 1280287
    [Abstract] [Full Text] [Related]

  • 9. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
    Münzer T, Rosen CJ, Harman SM, Pabst KM, St Clair C, Sorkin JD, Blackman MR.
    Am J Physiol Endocrinol Metab; 2006 May 20; 290(5):E1006-13. PubMed ID: 16390864
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels.
    Paassilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Bäckström AC, Kesäniemi YA.
    Atherosclerosis; 2000 Mar 20; 149(1):157-62. PubMed ID: 10704627
    [Abstract] [Full Text] [Related]

  • 11. [Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate].
    Milewicz T, Krzysiek J, Rogatko I, Sztefko K, Stochmal E, Hubalewska-Dydejczyk A, Jach R, Radowicki S.
    Ginekol Pol; 2011 Mar 20; 82(3):200-4. PubMed ID: 21735688
    [Abstract] [Full Text] [Related]

  • 12. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
    Raudaskoski T, Knip M, Laatikainen T.
    Menopause; 1998 Mar 20; 5(4):217-22. PubMed ID: 9872487
    [Abstract] [Full Text] [Related]

  • 13. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 20; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 14. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status.
    Gravholt CH, Svenstrup B, Bennett P, Sandahl Christiansen J.
    Clin Endocrinol (Oxf); 1999 Jun 20; 50(6):791-800. PubMed ID: 10468952
    [Abstract] [Full Text] [Related]

  • 15. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
    Suvanto-Luukkonen E, Sundström H, Penttinen J, Kauppila A.
    Arch Gynecol Obstet; 1998 Jun 20; 261(4):201-8. PubMed ID: 9789651
    [Abstract] [Full Text] [Related]

  • 16. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.
    Stomati M, Hartmann B, Spinetti A, Mailand D, Rubino S, Albrecht A, Huber J, Petraglia F, Genazzani AR.
    J Endocrinol Invest; 1996 Sep 20; 19(8):535-41. PubMed ID: 8905477
    [Abstract] [Full Text] [Related]

  • 17. Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism.
    van der Klaauw AA, Biermasz NR, Zelissen PM, Pereira AM, Lentjes EG, Smit JW, van Thiel SW, Romijn JA, Roelfsema F.
    Eur J Endocrinol; 2007 Dec 20; 157(6):709-16. PubMed ID: 18057377
    [Abstract] [Full Text] [Related]

  • 18. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.
    Wilson ME.
    J Clin Endocrinol Metab; 1998 Nov 20; 83(11):4013-21. PubMed ID: 9814485
    [Abstract] [Full Text] [Related]

  • 19. 17beta-estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypoestrogenic, hypergonadotropic women.
    Milewicz T, Krzysiek J, Sztefko K, Radowicki S, Krzyczkowska-Sendrakowska M.
    Endokrynol Pol; 2005 Nov 20; 56(6):876-82. PubMed ID: 16821205
    [Abstract] [Full Text] [Related]

  • 20. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
    Bellantoni MF, Harman SM, Cho DE, Blackman MR.
    J Clin Endocrinol Metab; 1991 Jan 20; 72(1):172-8. PubMed ID: 1824707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.